Hence, for the FDG measurements of the ER+ tumor response (Figure 7a), the uptake was significantly lower than the control group for fulvestrant at day 7 (p < 0.005) and day 14 (p < 0.01), and for letrozole at day 7 (p < 0.05). This evidence concerns the gene ESR1 and neoplasm.